{
  "input": {
    "mode": "revise",
    "query": {
      "entity": "Atypical haemolytic uraemic syndrome",
      "relation": "indication"
    },
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_eculizumab",
          "type": "Drug",
          "label": "Eculizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ravulizumab",
          "type": "Drug",
          "label": "Ravulizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_avacopan",
          "type": "Drug",
          "label": "Avacopan",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_complement_c5_inhibitors",
          "type": "Drug",
          "label": "Complement C5 Inhibitors",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cangrelor",
          "type": "Drug",
          "label": "Cangrelor",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_nivolumab",
          "type": "Drug",
          "label": "Nivolumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_eculizumab_biosimilar",
          "type": "Drug",
          "label": "Eculizumab Biosimilar",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tafamidis",
          "type": "Drug",
          "label": "Tafamidis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ertugliflozin",
          "type": "Drug",
          "label": "Ertugliflozin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_daratumumab",
          "type": "Drug",
          "label": "Daratumumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_obinutuzumab",
          "type": "Drug",
          "label": "Obinutuzumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_caplacizumab",
          "type": "Drug",
          "label": "Caplacizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "disease_a_hus",
          "type": "Disease",
          "label": "Atypical Haemolytic Uraemic Syndrome",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_c5",
          "type": "Target",
          "label": "C5 Complement Protein",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_complement_system",
          "type": "Pathway",
          "label": "Complement System Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_eculizumab",
          "type": "Target",
          "label": "OffTarget_Eculizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_eculizumab",
          "type": "Pathway",
          "label": "RiskPathway_Eculizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_eculizumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Eculizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_ravulizumab",
          "type": "Target",
          "label": "OffTarget_Ravulizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_ravulizumab",
          "type": "Pathway",
          "label": "RiskPathway_Ravulizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_ravulizumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Ravulizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_avacopan",
          "type": "Target",
          "label": "OffTarget_Avacopan",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_avacopan",
          "type": "Pathway",
          "label": "RiskPathway_Avacopan",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_avacopan",
          "type": "Phenotype",
          "label": "AdversePhenotype_Avacopan",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_c5_inhibitors",
          "type": "Target",
          "label": "OffTarget_C5_Inhibitors",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_c5_inhibitors",
          "type": "Pathway",
          "label": "RiskPathway_C5_Inhibitors",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_c5_inhibitors",
          "type": "Phenotype",
          "label": "AdversePhenotype_C5_Inhibitors",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Eculizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Ravulizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Avacopan",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Complement C5 Inhibitors",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Cangrelor",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Nivolumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Eculizumab Biosimilar",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Tafamidis",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Ertugliflozin",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Daratumumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Obinutuzumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Caplacizumab",
          "attrs": {
            "agent": "PI"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_eculizumab",
          "target": "target_c5",
          "relation": "inhibits",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "已知机制，多项研究支持其用于aHUS"
        },
        {
          "source": "drug_ravulizumab",
          "target": "target_c5",
          "relation": "inhibits",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "与eculizumab具有相似机制，预期疗效"
        },
        {
          "source": "drug_avacopan",
          "target": "pathway_complement_system",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "已知与补体系统交互的机制"
        },
        {
          "source": "drug_complement_c5_inhibitors",
          "target": "pathway_complement_system",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "补体抑制剂归入此类机制"
        },
        {
          "source": "drug_cangrelor",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "潜在关联性，有研究指向抗血小板作用"
        },
        {
          "source": "drug_nivolumab",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "需要进一步研究，但部分临床观察相关"
        },
        {
          "source": "drug_eculizumab_biosimilar",
          "target": "target_c5",
          "relation": "inhibits",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "作为原药物的生物仿制药，假设功能相似"
        },
        {
          "source": "drug_tafamidis",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.4,
          "agent": "Proponent",
          "rationale": "尚需验证但具有潜在机制的药物"
        },
        {
          "source": "drug_ertugliflozin",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "近期有初步研究显示效果"
        },
        {
          "source": "drug_daratumumab",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.4,
          "agent": "Proponent",
          "rationale": "针对特定病理机制，需深入探讨"
        },
        {
          "source": "drug_obinutuzumab",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.4,
          "agent": "Proponent",
          "rationale": "有针对性，初步数据待确认"
        },
        {
          "source": "drug_caplacizumab",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "已在临床试验中显示疗效"
        },
        {
          "source": "drug_eculizumab",
          "target": "n_ot_eculizumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对非靶点产生副作用"
        },
        {
          "source": "n_ot_eculizumab",
          "target": "n_rp_eculizumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路"
        },
        {
          "source": "n_rp_eculizumab",
          "target": "n_adv_eculizumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_eculizumab",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "drug_ravulizumab",
          "target": "n_ot_ravulizumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对非靶点产生副作用"
        },
        {
          "source": "n_ot_ravulizumab",
          "target": "n_rp_ravulizumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路"
        },
        {
          "source": "n_rp_ravulizumab",
          "target": "n_adv_ravulizumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_ravulizumab",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "drug_avacopan",
          "target": "n_ot_avacopan",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对非靶点产生副作用"
        },
        {
          "source": "n_ot_avacopan",
          "target": "n_rp_avacopan",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路"
        },
        {
          "source": "n_rp_avacopan",
          "target": "n_adv_avacopan",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_avacopan",
          "target": "H3",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "drug_complement_c5_inhibitors",
          "target": "n_ot_c5_inhibitors",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能对非靶点产生副作用"
        },
        {
          "source": "n_ot_c5_inhibitors",
          "target": "n_rp_c5_inhibitors",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在风险通路"
        },
        {
          "source": "n_rp_c5_inhibitors",
          "target": "n_adv_c5_inhibitors",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_c5_inhibitors",
          "target": "H4",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        }
      ],
      "round_index": 4
    },
    "history": {
      "round": 4,
      "last_scores": [
        {
          "hypothesis_id": "H1",
          "score": 0.77,
          "components": {
            "mechanism_fit": 0.9,
            "class_prior": 0.8,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.9,
            "safety_risk": 0.15,
            "graph_bonus": 0.2,
            "conflict_penalty": 0.1
          },
          "graph_signals": {
            "support_weight": 0.9,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险与副作用",
                "pro": [
                  "drug_eculizumab"
                ],
                "con": [
                  "n_adv_eculizumab"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Eculizumab已知抑制C5补体蛋白，与aHUS治疗相关"
            ],
            "safety_risk": [
              "潜在的非靶向副作用可能导致不良结果"
            ]
          },
          "confidence": "high",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H2",
          "score": 0.67,
          "components": {
            "mechanism_fit": 0.9,
            "class_prior": 0.7,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.8,
            "safety_risk": 0.15,
            "graph_bonus": 0.18,
            "conflict_penalty": 0.1
          },
          "graph_signals": {
            "support_weight": 0.9,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险与副作用",
                "pro": [
                  "drug_ravulizumab"
                ],
                "con": [
                  "n_adv_ravulizumab"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Ravulizumab是Eculizumab的同类药物，机制相似"
            ],
            "safety_risk": [
              "对非靶点的可能影响与不良反应的风险"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H3",
          "score": 0.58,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.6,
            "indication_plausibility": 0.7,
            "safety_risk": 0.15,
            "graph_bonus": 0.16,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.5,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": false,
            "path_disjointness": 0,
            "conflict_hotspots": [
              {
                "topic": "风险与副作用",
                "pro": [
                  "drug_avacopan"
                ],
                "con": [
                  "n_adv_avacopan"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Avacopan在补体相关机制中已知有调节作用"
            ],
            "safety_risk": [
              "副作用的潜在性风险需要重视"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H4",
          "score": 0.62,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.7,
            "safety_risk": 0.15,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.15
          },
          "graph_signals": {
            "support_weight": 0.8,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险与副作用",
                "pro": [
                  "drug_complement_c5_inhibitors"
                ],
                "con": [
                  "n_adv_c5_inhibitors"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "补体C5抑制剂理论上适用于aHUS的治疗"
            ],
            "safety_risk": [
              "风险与副作用需进一步研究"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H5",
          "score": 0.25,
          "components": {
            "mechanism_fit": 0.3,
            "class_prior": 0.4,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.3,
            "safety_risk": 0.15,
            "graph_bonus": 0.1,
            "conflict_penalty": 0.1
          },
          "graph_signals": {
            "support_weight": 0.6,
            "contradiction_weight": 0.3,
            "mechanistic_connectivity": false,
            "path_disjointness": 0,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Cangrelor的抗血小板作用与aHUS治疗相关性尚不明确"
            ],
            "safety_risk": []
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏临床证据支持"
          ]
        },
        {
          "hypothesis_id": "H6",
          "score": 0.3,
          "components": {
            "mechanism_fit": 0.4,
            "class_prior": 0.5,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.4,
            "safety_risk": 0.15,
            "graph_bonus": 0.08,
            "conflict_penalty": 0.1
          },
          "graph_signals": {
            "support_weight": 0.5,
            "contradiction_weight": 0.25,
            "mechanistic_connectivity": false,
            "path_disjointness": 0,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Nivolumab的适应症与aHUS没有明确关联"
            ],
            "safety_risk": []
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏相关机制证据"
          ]
        },
        {
          "hypothesis_id": "H7",
          "score": 0.65,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.8,
            "safety_risk": 0.15,
            "graph_bonus": 0.18,
            "conflict_penalty": 0.12
          },
          "graph_signals": {
            "support_weight": 0.9,
            "contradiction_weight": 0.85,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险与副作用",
                "pro": [
                  "drug_eculizumab_biosimilar"
                ],
                "con": [
                  "n_adv_eculizumab"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Eculizumab的生物仿制药，假设机制相似"
            ],
            "safety_risk": [
              "潜在的副作用与仿制药的效果有关"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        },
        {
          "hypothesis_id": "H8",
          "score": 0.28,
          "components": {
            "mechanism_fit": 0.2,
            "class_prior": 0.3,
            "pk_pd_feasibility": 0.2,
            "indication_plausibility": 0.3,
            "safety_risk": 0.15,
            "graph_bonus": 0.06,
            "conflict_penalty": 0.08
          },
          "graph_signals": {
            "support_weight": 0.3,
            "contradiction_weight": 0.25,
            "mechanistic_connectivity": false,
            "path_disjointness": 0,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Tafamidis与补体系统的关系尚不明确"
            ],
            "safety_risk": []
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏针对aHUS的临床数据"
          ]
        },
        {
          "hypothesis_id": "H9",
          "score": 0.12,
          "components": {
            "mechanism_fit": 0.2,
            "class_prior": 0.2,
            "pk_pd_feasibility": 0.2,
            "indication_plausibility": 0.1,
            "safety_risk": 0.15,
            "graph_bonus": 0.03,
            "conflict_penalty": 0.08
          },
          "graph_signals": {
            "support_weight": 0.2,
            "contradiction_weight": 0,
            "mechanistic_connectivity": false,
            "path_disjointness": 0,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Ertugliflozin的机制与aHUS无关"
            ],
            "safety_risk": []
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏相关证据支持"
          ]
        },
        {
          "hypothesis_id": "H10",
          "score": 0.22,
          "components": {
            "mechanism_fit": 0.2,
            "class_prior": 0.3,
            "pk_pd_feasibility": 0.2,
            "indication_plausibility": 0.3,
            "safety_risk": 0.15,
            "graph_bonus": 0.06,
            "conflict_penalty": 0.08
          },
          "graph_signals": {
            "support_weight": 0.4,
            "contradiction_weight": 0,
            "mechanistic_connectivity": false,
            "path_disjointness": 0,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Daratumumab的与aHUS的关联需要进一步探讨"
            ],
            "safety_risk": []
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏明确临床证据"
          ]
        },
        {
          "hypothesis_id": "H11",
          "score": 0.15,
          "components": {
            "mechanism_fit": 0.2,
            "class_prior": 0.2,
            "pk_pd_feasibility": 0.2,
            "indication_plausibility": 0.2,
            "safety_risk": 0.15,
            "graph_bonus": 0.03,
            "conflict_penalty": 0.08
          },
          "graph_signals": {
            "support_weight": 0.1,
            "contradiction_weight": 0,
            "mechanistic_connectivity": false,
            "path_disjointness": 0,
            "conflict_hotspots": []
          },
          "rationales": {
            "mechanism_fit": [
              "Obinutuzumab在补体疾病中的作用尚不明确"
            ],
            "safety_risk": []
          },
          "confidence": "low",
          "uncertainties": [
            "缺乏针对性机制的数据"
          ]
        },
        {
          "hypothesis_id": "H12",
          "score": 0.6,
          "components": {
            "mechanism_fit": 0.8,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.7,
            "indication_plausibility": 0.6,
            "safety_risk": 0.15,
            "graph_bonus": 0.14,
            "conflict_penalty": 0.1
          },
          "graph_signals": {
            "support_weight": 0.85,
            "contradiction_weight": 0.45,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "风险与副作用",
                "pro": [
                  "drug_caplacizumab"
                ],
                "con": [
                  "n_adv_c5_inhibitors"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Caplacizumab已展示在aHUS中的潜在疗效"
            ],
            "safety_risk": [
              "副作用及风险控制需关注"
            ]
          },
          "confidence": "medium",
          "uncertainties": []
        }
      ]
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "revisions": [
      {
        "hypothesis_id": "H1",
        "graph_actions": [
          {
            "type": "add_mechanism_link",
            "from": "drug_eculizumab",
            "via": [
              "target_c5"
            ],
            "to": "disease_a_hus",
            "success_criteria": "形成至少2条不相交路径",
            "assignee": "Proponent"
          },
          {
            "type": "stress_test_safety",
            "topic": "非靶向副作用",
            "expectation": "若风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "Eculizumab在aHUS治疗中的效益与非靶向副作用的权衡"
        ]
      },
      {
        "hypothesis_id": "H2",
        "graph_actions": [
          {
            "type": "add_mechanism_link",
            "from": "drug_ravulizumab",
            "via": [
              "target_c5"
            ],
            "to": "disease_a_hus",
            "success_criteria": "形成至少2条不相交路径",
            "assignee": "Proponent"
          },
          {
            "type": "stress_test_safety",
            "topic": "非靶向副作用",
            "expectation": "若风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "Ravulizumab的机制与可能不良反应的细节"
        ]
      },
      {
        "hypothesis_id": "H3",
        "graph_actions": [
          {
            "type": "add_mechanism_link",
            "from": "drug_avacopan",
            "via": [
              "pathway_complement_system"
            ],
            "to": "disease_a_hus",
            "success_criteria": "形成至少2条不相交路径",
            "assignee": "Proponent"
          },
          {
            "type": "stress_test_safety",
            "topic": "非靶向副作用",
            "expectation": "若风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "Avacopan与补体系统之间的相互作用及潜在风险"
        ]
      },
      {
        "hypothesis_id": "H4",
        "graph_actions": [
          {
            "type": "add_mechanism_link",
            "from": "drug_complement_c5_inhibitors",
            "via": [
              "pathway_complement_system"
            ],
            "to": "disease_a_hus",
            "success_criteria": "形成至少2条不相交路径",
            "assignee": "Proponent"
          },
          {
            "type": "stress_test_safety",
            "topic": "非靶向副作用",
            "expectation": "若风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ],
        "debate_focus": [
          "C5抑制剂在aHUS中的安全性与有效性"
        ]
      }
    ],
    "pruned_hypotheses": [
      "H5",
      "H6",
      "H8",
      "H9",
      "H10",
      "H11"
    ],
    "seed_request": {
      "should_regenerate": false,
      "reason": "存在多个机制连通性不足的候选，且同一领域中不应排斥其他机制的潜在路径关系，应通过补链提升Path_Disjointness。",
      "n": 4
    }
  }
}